# Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)

> **NCT03463733** · PHASE1 · UNKNOWN · sponsor: **M.E. van Linde** · enrollment: 54 (estimated)

## Conditions studied

- Glioma
- Glioblastoma

## Interventions

- **DRUG:** Hydroxyurea
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT03463733
- **Lead sponsor:** M.E. van Linde
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-02
- **Primary completion:** 2021-06-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2020-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03463733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03463733, "Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03463733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*